OPEN-LABEL STUDY in Croatian translation

• otvorenom ispitivanju
• otvoreno ispitivanje
• otvorenog ispitivanja

Examples of using Open-label study in English and their translations into Croatian

For example, an open-label study found that the 9 women who were participating lost an average of 2.40 kg, when the supplement was taken, and only 0.94 kg when placebo was used.
Na primjer, istraživanje otvorenog nalaza pokazalo je da su žene 9 koje su sudjelovale izgubile prosječno 2.4 kg, kada je uzimana dodatak, a samo 0.94 kg u placebo.

A single-dose, open-label study was conducted to evaluate the pharmacokinetics of 60 mg lomitapide in healthy volunteers with normal hepatic function compared with patients with mild(Child-Pugh A)
Otvoreno ispitivanje s jednostrukom dozom provedeno je kako bi se procijenila farmakokinetika doze lomitapida od 60 mg u zdravih dobrovoljaca s normalnom funkcijom jetre,

A single-dose, open-label study was conducted to evaluate the pharmacokinetics of a reduced dose of sitagliptin(50 mg)
U provedenom otvorenom ispitivanju primjene jedne doze lijeka utvrđivala se farmakokinetika snižene doze sitagliptina(50 mg)

Study PACTG 382 was an open-label study to evaluate the pharmacokinetics,
Ispitivanje PACTG 382 bilo je otvoreno ispitivanje za procjenu farmakokinetike,

controlled, open-label study which accrued patients in the early phase of aHUS with evidence of clinical thrombotic microangiopathy manifestations with platelet count≤ 150 x 109/L despite PE/PI,
kontrolirano ispitivanje otvorenog tipa koje je uključilo bolesnike u ranoj fazi aHUS-a s dokazanim kliničkim manifestacijama trombotične mikroangiopatije, brojem trombocita ≤150 x 109/l usprkos PE/PI

an improvement in diastolic relaxation in an open-label study of 5 patients with a long QT syndrome LQT3 having the SCN5A∆KPQ gene mutation.
skraćenju QTc intervala i poboljšanju dijastoličke relaksacije u otvorenoj studiji na 5 bolesnika sa sindromom dugog QT LQT3 sa SCN5A ∆KPQ mutacijom gena.

In an open-label study carried out by the Cancer and Leukaemia Group B
U otvorenom ispitivanju koje je provela Skupina B za istraživanje raka

In this open-label study, 443 patients already on an antiviral regimen containing Viramune 200 mg immediate-release twice daily with HIV-1 RNA<
U ovom otvorenom ispitivanju, 443 bolesnika na antivirusnom režimu Viramuneom 200 mg s trenutnim oslobađanjem dvaput dnevno s HIV-1 RNK< 50 kopija/ml bili

ION-2 was a randomised, open-label study that evaluated 12 and 24 weeks of treatment with ledipasvir/sofosbuvir with
ION-2 bilo je randomizirano, otvoreno ispitivanje kojim se procijenilo 12 i 24 tjedna liječenja ledipasvirom/ sofosbuvirom s ribavirinom

randomized open-label study versus single agent of investigator's choice in patients who were refractory to their last regimen
randomiziranom, otvorenom ispitivanju faze II, u usporedbi s primjenom samo jednog lijeka prema izboru liječnika

randomised, open-label study that evaluated the pharmacokinetic profile,
randomizirano, otvoreno ispitivanje u kojem je ocijenjen farmakokinetički profil,

on 24-week data from a randomised, open-label study in patients who transitioned from Viramune immediate-release tablets administered twice daily to Viramune prolonged-release tablets administered once daily TRANxITION- study 1100.1526.
na 24-tjednim podacima iz randomiziranog, otvorenog ispitivanja na bolesnicima koji su se prebacili s Viramune tableta s trenutnim oslobađanjem dvaput dnevno na Viramune tablete s produljenim oslobađanjem jednom dnevno TRANxITION- ispitivanje 1100.1526.

open-label extension phase and one was a 24-week open-label study.
jedno je bilo otvoreno ispitivanje u trajanju od 24 tjedna.

In an open-label study, 24 paediatric patients(n=10, age 1 to≤
Fondaparinuks je primijenjen u ispitivanju otvorenog tipa, na 24 pedijatrijska bolesnika(n 10,

controlled, open-label study which accrued patients with longer term aHUS without apparent evidence of clinical thrombotic microangiopathy manifestations
kontrolirano ispitivanje otvorenog tipa koje je uključilo bolesnike s dugotrajnijim aHUS-om bez kliničkih manifestacija trombotične mikroangiopatije, koji su kronično

randomised, open-label study with 74 and 76 patients in each treatment group.
randomiziranom ispitivanju otvorenog tipa u dvije terapijske skupine, jedne sa 74 i druge sa 76 bolesnika.

randomised, open-label study( CC-4047-MM-003), where pomalidomide plus low-dose dexamethasone therapy( Pom+LD-Dex)
randomiziranom, otvorenom ispitivanju faze III( CC-4047-MM-003), u kojem je terapija pomalidomidom s niskom dozom deksametazoma( Pom+ LD-Dex)

controlled, open-label study comparing the effect of adding Avastin to carboplatin
kontrolirano, otvoreno ispitivanje faze III, s dvije skupine, koje je uspoređivalo

Six open-label studies evaluated Oncaspar in relapse/refractory haematological diseases.
Šest otvorenih ispitivanja procjenjivalo je Oncaspar u relapsnim/refraktornim hematološkim bolestima.

Therefore the studies were performed as open-label studies.
Stoga su ispitivanja provedena kao ispitivanja otvorenog tipa.